Edwards Lifesciences Corp

EW

Equity

ISIN US28176E1082 / Valor 1065343

New York Stock Exchange, Inc (2024-09-18)

USD 67.53+0.45%

Edwards Lifesciences Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Edwards Lifesciences Corp is a global leader in the development and research of heart valve therapies and hemodynamic monitoring systems. Founded in 1958 by Miles "Lowell" Edwards, the company has a long history of innovation in the field of cardiovascular technology. Edwards Lifesciences specializes in creating advanced medical technologies aimed at treating structural heart diseases and providing critical care monitoring solutions. The company collaborates closely with physicians to develop products that enhance the lives of patients by extending longevity, improving health, and increasing productivity. Headquartered in Irvine, California, Edwards Lifesciences serves almost 100 countries worldwide, delivering products and technologies that address the needs of large and growing patient populations with unmet medical requirements.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Edwards Lifesciences Corp reported a 7% increase in sales for the second quarter of 2024, with constant currency sales growing by 8%. This growth was driven by strong contributions from the Transcatheter Mitral and Tricuspid Therapies (TMTT) product group, which saw a significant 75% increase in sales.

Earnings Per Share

For the second quarter of 2024, Edwards Lifesciences Corp reported earnings per share (EPS) of $0.61. On an adjusted basis, the EPS was $0.70, benefiting from a lower-than-expected adjusted tax rate of 8.4%.

Transcatheter Aortic Valve Replacement (TAVR) Sales

Edwards Lifesciences Corp's TAVR sales for the second quarter of 2024 were $1.0 billion, reflecting a 5% growth, or 6% on a constant currency basis. The company maintained its competitive position globally, despite some regional pressures, and began introducing the SAPIEN 3 Ultra RESILIA valve in Europe.

Transcatheter Mitral and Tricuspid Therapies (TMTT) Sales

In the second quarter of 2024, Edwards Lifesciences Corp reported TMTT sales of $83 million, led by the PASCAL repair system and the early commercial introduction of the EVOQUE system in the U.S. and Europe. The company noted strong demand and excellent clinical results for these therapies.

Outlook for 2024

Edwards Lifesciences Corp expects full-year 2024 sales growth of 8 to 10%, with TAVR sales growth adjusted to 5 to 7% from the previous 8 to 10%. The company also increased its TMTT sales guidance to the higher end of the $320 to $340 million range, reflecting strong first-half momentum.

Summarized from source with an LLMView Source

Key figures

-7.42%1Y

-43.5%3Y

-7.00%5Y

Performance

46.6%1Y

39.2%3Y

37.5%5Y

Volatility